285 related articles for article (PubMed ID: 30993904)
1. Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma.
Song Y; Chen D; Zhang X; Luo Y; Li S
Thorac Cancer; 2019 May; 10(5):1220-1228. PubMed ID: 30993904
[TBL] [Abstract][Full Text] [Related]
2. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
3. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
4. High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma.
Li X; Liu M; Zhang Z; Zhang L; Liang X; Sun L; Zhong D
Thorac Cancer; 2019 May; 10(5):1103-1110. PubMed ID: 30907518
[TBL] [Abstract][Full Text] [Related]
5. Co-expression network analysis identified KIF2C in association with progression and prognosis in lung adenocarcinoma.
Bai Y; Xiong L; Zhu M; Yang Z; Zhao J; Tang H
Cancer Biomark; 2019; 24(3):371-382. PubMed ID: 30883337
[TBL] [Abstract][Full Text] [Related]
6. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
7. Genetic analyses of differences between solid and nonsolid predominant lung adenocarcinomas.
Luo J; Ma K; Shi Y; Chen Z; Zhao M; Huang Y; Wang S; Xi J; Zhan C; Xu S; Wang Q
Thorac Cancer; 2018 Dec; 9(12):1656-1663. PubMed ID: 30276966
[TBL] [Abstract][Full Text] [Related]
8. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
9. Systematical identifications of prognostic meaningful lung adenocarcinoma subtypes and the underlying mutational and expressional characters.
Lv Z; Lei T
BMC Cancer; 2020 Jan; 20(1):56. PubMed ID: 31987030
[TBL] [Abstract][Full Text] [Related]
10. A gene expression-based immune signature for lung adenocarcinoma prognosis.
Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a nomogram with an epigenetic signature for predicting survival in patients with lung adenocarcinoma.
Wang J; He L; Tang Y; Li D; Yang Y; Zeng Z
Aging (Albany NY); 2020 Nov; 12(22):23200-23216. PubMed ID: 33221751
[TBL] [Abstract][Full Text] [Related]
12. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
[TBL] [Abstract][Full Text] [Related]
13. Eight-gene signature predicts recurrence in lung adenocarcinoma.
Zhang Y; Fan Q; Guo Y; Zhu K
Cancer Biomark; 2020; 28(4):447-457. PubMed ID: 32508318
[TBL] [Abstract][Full Text] [Related]
14. Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma.
Li B; Huang Z; Yu W; Liu S; Zhang J; Wang Q; Wu L; Kou F; Yang L
Neoplasia; 2021 Jul; 23(7):704-717. PubMed ID: 34139453
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
16. A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
Jiang H; Xu S; Chen C
BMC Cancer; 2020 Aug; 20(1):782. PubMed ID: 32819300
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
Wang W; Ren S; Wang Z; Zhang C; Huang J
Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
[TBL] [Abstract][Full Text] [Related]
18. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z
BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel CD74-NRG2α Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers.
Kohsaka S; Hayashi T; Nagano M; Ueno T; Kojima S; Kawazu M; Shiraishi Y; Kishikawa S; Suehara Y; Takahashi F; Takahashi K; Suzuki K; Takamochi K; Mano H
J Thorac Oncol; 2020 Jun; 15(6):948-961. PubMed ID: 32036070
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
Zhao Y; Gao Y; Xu X; Zhou J; Wang H
BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
